Treatment
Carvedilol clinical trials
We’re tracking 18 recruiting studies that include Carvedilol, each written for real people, not researchers, below.
Recruiting studies
- NCT06594783RecruitingPhase 4
Preventing varices bleeding with carvedilol and banding
This trial tests whether adding endoscopic banding helps prevent bleeding from enlarged varices in people with cirrhosis who still have high-risk varices despite taking carvedilol.
TaipeiAges 18–90 - NCT07352228Enrolling by invitationPhase 4
Comparing carvedilol and propranolol to prevent variceal rebleeding
This trial tests whether carvedilol or propranolol works better to prevent another bleeding episode from enlarged veins in the stomach or esophagus (varices) after they have been treated with endoscopy. If you have cirrhosis and had a variceal bleed 6 to 30 days ago, this study may help find the most effective medicine for you.
Xi'anAges 18–75 - NCT06431919Recruiting
Adding statin to carvedilol for cirrhosis with heart problems
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
ChandigarhAges 18–65 - NCT07108075Recruiting
Testing metformin and carvedilol for cirrhosis with variceal bleeding
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
New Delhi, National Capital Territory of DelhiAges 18–75 - NCT07322237RecruitingPhase 4
Study on heart function drugs for liver cirrhosis patients
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
ChandigarhAges 18–65 - NCT01212250Recruiting
Carvedilol to prevent esophagus bleeding in cirrhosis
This trial tests whether carvedilol can prevent the first development of swollen veins (varices) in the esophagus in people with cirrhosis who do not have them yet. It may help lower the risk of future bleeding from those veins.
New Delhi, National Capital Territory of DelhiAges 18–75 - NCT06861075Recruiting
Carvedilol for high blood pressure in liver veins
This trial tests whether a medicine called carvedilol can lower high blood pressure in the liver veins of people with cirrhosis. It uses a special ultrasound probe to measure the pressure before and after taking the medicine.
Clermont-FerrandAges 18 years+ - NCT04499898RecruitingPhase 2/Phase 3
Carvedilol vs banding to prevent first bleeding from esophageal veins
This trial compares two ways to prevent bleeding from enlarged veins in the food pipe (esophageal varices) in people with cirrhosis. It tests whether carvedilol (a blood-pressure/heart medicine) works as well as an endoscopic procedure that places small bands to reduce bleeding risk.
TantaAges 18 years+ - NCT06594744RecruitingPhase 4
Preventing first bleeding from varices in liver cancer patients
This trial compares two treatments (banding or a medication called carvedilol) to prevent the first episode of bleeding from enlarged veins in the esophagus in people with liver cancer. The goal is to find which approach is safer and more effective.
TaipeiAges 20–90 - NCT06964464RecruitingPhase 4
Comparing two heart failure medications in ICD patients
This trial compares two beta-blocker medications, carvedilol and metoprolol succinate, to see which one works better for people with heart failure who have an implantable cardioverter defibrillator (ICD). If you are currently taking metoprolol succinate, you may be able to switch to carvedilol and help researchers find the best treatment.
Scottsdale, ArizonaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT05931276RecruitingPhase 3
Beta blocker choice may improve heart outcomes on dialysis
This phase 3 study tests whether a specific beta blocker selection on hemodialysis can improve cardiovascular outcomes. It focuses on certain beta blockers commonly used through the VA pharmacy and compares them in a randomized way.
Long Beach, CaliforniaAges 18 years+ - NCT06078436Recruiting
Early carvedilol for heart failure shock
This trial tests whether starting the heart failure medication carvedilol early, along with standard monitoring, can help people in cardiogenic shock (when the heart can't pump enough blood) due to a weak heart muscle. It aims to see if earlier treatment improves outcomes.
SeoulAges 19 years+ - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT05194111RecruitingPhase 1/Phase 2
Heart medication study for cancer survivors with mild heart weakness
This study tests a heart medication (sacubitril/valsartan) in young cancer survivors whose hearts were weakened by anthracycline chemotherapy but are not yet having heart failure symptoms. It aims to see if the drug can improve heart function and prevent future problems.
Richmond, VirginiaAges 18–120 - NCT06643221RecruitingEarly Phase 1
Exercise as a booster for cell therapy treatments
This trial tests whether exercise and a heart medicine called isoproterenol can help your immune system work better with donor cell therapies. It may show how to make these treatments more effective.
Tucson, ArizonaAges 21–55 - NCT06836856RecruitingPhase 1/Phase 2
Beta blockers after traumatic brain injury: a study
This trial tests whether giving a beta blocker drug after a moderate or severe traumatic brain injury can improve recovery. It is for patients who have a brain injury but only minor or no other injuries.
ZagazigAges 18–75 - NCT07521332RecruitingPhase 4
Testing Apixaban to Prevent Bleeding Complications in Cirrhosis
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
Hyderābād, SindhAges 18 years+
What Carvedilol is being studied for
Conditions with recruiting Carvedilol studies.
Common questions
- Are there clinical trials studying Carvedilol?
- Yes. Clin2 currently lists 18 recruiting studies that include Carvedilol, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Carvedilol trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Carvedilol an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Carvedilol or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.